Clinical Trial Update: REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism [Phase 2]

View source ↗

Summary

Phase 2 trial REVERSE is investigating glucocorticoid receptor antagonism for treatment-resistant PTSD and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Glucocorticoid receptor antagonist

Snippet

Sponsor: Christiaan Vinkers | Conditions: Treatment-resistant PTSD | Phase 2 | Status: RECRUITING